naproxen has been researched along with tolrestat in 5 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (tolrestat) | Trials (tolrestat) | Recent Studies (post-2010) (tolrestat) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 198 | 25 | 14 |
| Protein | Taxonomy | naproxen (IC50) | tolrestat (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.0244 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.2689 | |
| Aldo-keto reductase family 1 member A1 | Homo sapiens (human) | 1.1533 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.2303 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.096 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.043 | |
| Aldo-keto reductase family 1 member A1 | Sus scrofa (pig) | 1.365 | |
| Aldo-keto reductase family 1 member A1 | Rattus norvegicus (Norway rat) | 1.21 | |
| Aldo-keto reductase family 1 member B1 | Sus scrofa (pig) | 0.0225 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for naproxen and tolrestat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for naproxen and tolrestat
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |